SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-000123
Filing Date
2024-01-03
Accepted
2024-01-03 08:00:20
Documents
13
Period of Report
2024-01-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K espr-20240102.htm   iXBRL 8-K 32892
2 EX-99.1 dsepressrelease.htm EX-99.1 16397
  Complete submission text file 0001628280-24-000123.txt   184640

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT espr-20240102.xsd EX-101.SCH 1917
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT espr-20240102_lab.xml EX-101.LAB 24851
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT espr-20240102_pre.xml EX-101.PRE 13060
7 EXTRACTED XBRL INSTANCE DOCUMENT espr-20240102_htm.xml XML 2835
Mailing Address 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108
Business Address 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR MI 48108 734-887-3903
Esperion Therapeutics, Inc. (Filer) CIK: 0001434868 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35986 | Film No.: 24504381
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)